Mean change from baseline to 52 weeks in NEI VFQ-25 composite score ( pooled data ) stratified by clinical response showed meaningful improvement only in patients who gained 5 Early Treatment Diabetic Retinopathy letters or more ( 7.3 and 7.8 points for intravitreal aflibercept 2q8 and ranibizumab 0.5 q4 , respectively ) .